Combined Immunotherapies in Metastatic ER+ Breast Cancer
NCT04563507
This study is recruiting at 3 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 90 years
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Weill Medical College of Cornell University
- Last updated on ClinicalTrials.gov
- December 15, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 3
- Brooklyn Methodist Hospital - NewYork Presbyterian · New York, NY
- New York Presbyterian Hospital - Queens · New York, NY
- Weill Cornell Medicine · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.